Children

2
Pipeline Programs
3
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
ACE InhibitionPhase 3
Alder Therapeutics
Alder TherapeuticsSweden - Solna
1 program
1
Remifentanil and/or propofolPhase 31 trial
Active Trials
NCT02481791Unknown35Est. Dec 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Alder TherapeuticsRemifentanil and/or propofol

Clinical Trials (1)

Total enrollment: 35 patients across 1 trials

NCT02481791Alder TherapeuticsRemifentanil and/or propofol

Study to Evaluate the Optimal Dose of Remifentanil During MRI of the Heart Under General Anaesthesia

Start: Jul 2015Est. completion: Dec 201935 patients
Phase 3Unknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space